We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Genius Group Limited | AMEX:GNS | AMEX | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
-0.0065 | -1.67% | 0.3829 | 0.3909 | 0.38 | 0.39 | 1,045,841 | 00:59:31 |
CHALLENGING MARKETS – MANAGEMENT ACTIONS TAKEN
WEBCAST AVAILABLE TODAY AT 7:01 AM GMT, 2.01 EST
Genus (LSE:GNS), a leading global animal genetics company, today announces its interim results for the six months ended 31 December 2023. The full report has been made available on the investors section of the Genus plc website. The Company will discuss its corporate, operational and financial highlights in a pre-recorded webcast at 7:01 AM GMT, 2.01 EST.
Commenting on the performance and outlook, Jorgen Kokke, Chief Executive, said:
“Genus faced challenging markets which impacted performance in the first half of the year. We have taken rapid action including initiating a comprehensive programme to accelerate the value delivery from our bovine operations. We have also completed a strategic review of R&D activities. The Company is benefitting from savings achieved in the first half and will benefit further in the second half of the year and into FY25, as we optimise resource allocation to best deliver our growth objectives.
In North America, Europe and Latin America PIC continued to achieve growth in royalty revenues and operating profit, illustrating the strength of PIC’s business model. China continues to be a challenging porcine market, however enhanced commercial focus is delivering results. New royalty customers were signed in the first half which gives us more confidence that our sales approach is effective. The opportunity in China remains significant and given the success of the relationship with our local partner, BCA, we are jointly exploring ways to accelerate our collaboration going forward.
ABS saw weakness across most markets. China dairy was particularly challenging; not only did conventional volumes suffer from a double-digit decline in the dairy herd, but mix was also impacted as demand for sexed genetics reduced.
As described in our recent trading update, taking into account management actions taken, and assuming that present market conditions persist for the balance of the fiscal year, management expects fiscal year 2024 adjusted profit before tax to be not less than £58m in actual currency. We are seeing the positive impact of our actions to accelerate value delivery which will deliver further benefit in the second half and in subsequent years.”
Outlook
Conditions remain challenging for our customers in several parts of the world and we have driven acceleration of our value delivery initiatives to improve performance in the first half, with further action being taken in the second half. Our focus is on driving commercial excellence and efficiency improvements at ABS as well as concentrating our R&D efforts on projects with the most attractive commercial outcomes.
With management actions taken, and assuming that present market conditions persist for the balance of the fiscal year, management expects fiscal year 2024 adjusted profit before tax to be not less than £58m in actual currency1. Management remains committed to strong profit growth in the medium-term.
Results presentation today
A pre-recorded analysts and bankers briefing to discuss the interim results for the six months ended 31 December 2023 will be held via a video webcast facility and will be accessible via the following link from 7:01am today:
https://stream.buchanan.uk.com/broadcast/65a7b66cc5ec665c02ecf7b9
An archived recording of the webcast will also be available on the Investors section of the Company’s website.
Results Highlights
Adjusted results1
Statutory results
Actual currency
Constant currency change2
Actual currency
Six months ended 31 December
2023
2022
Change
2023
2022
Change
£m
£m
%
%
£m
£m
%
Revenue
333.6
350.2
(5)
1
333.6
350.2
(5)
Operating profit
33.0
41.2
(20)
(14)
21.3
14.7
45
Operating profit inc JVs
38.1
48.3
(21)
(17)
n/a
n/a
n/a
Profit before tax
29.2
42.2
(31)
(26)
14.3
15.0
(5)
Free cash flow
(3.3)
(3.3)
-
n/m3
Basic earnings per share (pence)
33.3
48.8
(32)
(27)
20.6
20.4
1
Dividend per share (pence)
10.3
10.3
-
Resilient revenue delivery amidst challenging markets
As expected, first half adjusted profit performance lower year on year
Reporting format change
Product Development costs now being allocated to PIC and ABS, having previously been reported within the R&D division; management has determined that this better aligns the costs as well as the opportunities of this activity with the businesses; no change to group adjusted operating profit.
Divisional headlines
1
Adjusted results are the Alternative Performance Measures (‘APMs’) used by the Board to monitor underlying performance at a Group and operating segment level, which are applied consistently throughout. These APMs should be considered in addition to, and not as a substitute for or as superior to statutory measures. For more information on APMs, see APM Glossary.
2
Constant currency percentage movements are calculated by restating the results for the six months ended 31 December 2023 at the average exchange rates applied to adjusted operating profit for the year ended 30 June 2023. Percentages are calculated on prior period restated figures. Please see Note 1 on the notes to the condensed set of Financial Statements changes of reportable segments
3
n/m = not meaningful
About Genus
Genus advances animal breeding and genetic improvement by applying biotechnology and sells added value products for livestock farming and food producers. Its technology is applicable across livestock species and is currently commercialised by Genus in the dairy, beef and pork food production sectors.
Genus's worldwide sales are made in over 85 countries under the trademarks 'ABS' (dairy and beef cattle) and 'PIC' (pigs) and comprise semen, embryos and breeding animals with superior genetics to those animals currently in farms. Genus's customers' animals produce offspring with greater production efficiency and quality, and our customers use them to supply the global dairy and meat supply chains.
Genus’s competitive edge comes from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and its global supply chain, technical service and sales and distribution network.
Headquartered in Basingstoke, United Kingdom, Genus companies operate in over 24 countries on six continents, with research laboratories located in Madison, Wisconsin, USA.
Forward-looking Statements
This Announcement may contain, and the Company may make verbal statements containing “forward-looking statements” with respect to certain of the Company’s plans and its current goals and expectations relating to its future financial condition, performance, strategic initiatives, objectives and results. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this Announcement. Forward-looking statements sometimes use words such as “aim”, “anticipate”, “target”, “expect”, “estimate”, “intend”, “plan”, “goal”, “believe”, “seek”, “may”, “could”, “outlook”, “will” or other words of similar meaning. By their nature, all forward-looking statements involve risk and uncertainty because they relate to future events and circumstances which are beyond the control of the Company, including amongst other things, diverse factors such as domestic and global economic business conditions, market-related risks such as fluctuations in commodity prices, interest rates and exchange rates, the policies and actions of governmental and regulatory authorities, the effect of competition, inflation, deflation, the timing effect and other uncertainties of future acquisitions or combinations within relevant industries, the rate of on-going porcine re-stocking in China after African Swine Fever, the continued development and improvement of our IntelliGen® technology, the development and registration of our innovative new products, such as our gene edited porcine reproductive and respiratory syndrome virus resistant pigs, the continued growth in emerging markets, the effect of tax and other legislation and other regulations in the jurisdictions in which the Company and its respective affiliates operate, the effect of volatility in the equity, capital and credit markets on the Company’s profitability and ability to access capital and credit, a decline in the Company’s credit ratings; the effect of operational risks; and the loss of key personnel. As a result, the actual future financial condition, performance and results of the Company may differ materially from the plans, goals and expectations set forth in any forward-looking statements. Except as required by applicable law or regulation, the Company expressly disclaims any obligation or undertaking to publish any updates or revisions to any forward-looking statements contained in this Announcement to reflect any changes in the Company’s expectations with regard thereto or any changes in events, conditions or circumstances on which any such statement is based.
No statement in this Announcement is intended to be a profit forecast, and no statement in this Announcement should be interpreted to mean that earnings per share of the Company for the current or future financial years would necessarily match or exceed the historical published earnings per share of the Company. Information contained in this Announcement should not be relied upon as a guide to the Company’s future performance.
This announcement is available on the Genus website www.genusplc.com
GENUS PLC
CONDENSED CONSOLIDATED INCOME STATEMENT
For the six months ended 31 December 2023
Six months ended 31 December 2023 £m
Six months ended 31 December
2022 £m
Year ended 30 June
2023 £m
REVENUE
333.6
350.2
689.7
Adjusted operating profit
33.0
41.2
74.6
Adjusting items:
– Net IAS 41 valuation movement on biological assets
2.6
(17.2)
(16.9)
– Amortisation of acquired intangible assets
(2.9)
(4.8)
(7.7)
– Share-based payment expense
(3.9)
(2.3)
(6.0)
(4.2)
(24.3)
(30.6)
Exceptional items (net)
(7.5)
(2.2)
(3.5)
Total adjusting items
(11.7)
(26.5)
(34.1)
OPERATING PROFIT
21.3
14.7
40.5
Share of post-tax profit of joint ventures and associates retained
5.3
6.4
10.5
Other gains and losses
(3.4)
-
2.7
Finance costs
(11.0)
(6.1)
(15.4)
Finance income
2.1
-
1.1
PROFIT BEFORE TAX
14.3
15.0
39.4
Taxation
(4.0)
(3.0)
(7.6)
PROFIT FOR THE PERIOD
10.3
12.0
31.8
ATTRIBUTABLE TO:
Owners of the Company
13.5
13.4
33.3
Non-controlling interest
(3.2)
(1.4)
(1.5)
10.3
12.0
31.8
EARNINGS PER SHARE
Basic earnings per share
20.6p
20.4p
50.8p
Diluted earnings per share
20.4p
20.3p
50.5p
Alternative Performance Measures
Adjusted operating profit
33.0
41.2
74.6
Adjusted operating loss attributable to non–controlling interest
0.4
0.2
0.4
Pre–tax share of profits from joint ventures and associates excluding net IAS 41 valuation movement
4.7
6.9
10.8
Adjusted operating profit including joint ventures and associates
38.1
48.3
85.8
Net finance costs
(8.9)
(6.1)
(14.3)
Adjusted profit before tax
29.2
42.2
71.5
Adjusted earnings per share
Basic adjusted earnings per share
33.3p
48.8p
84.8p
Diluted adjusted earnings per share
33.1p
48.5p
84.2p
Adjusted results are the Alternative Performance Measures (‘APMs’) used by the Board to monitor underlying performance at a Group and operating segment level, which are applied consistently throughout. These APMs should be considered in addition to statutory measures, and not as a substitute for or as superior to them. For more information on APMs, see APM Glossary.
GENUS PLC
CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
For the six months ended 31 December 2023
Six months ended 31 December 2023
Six months ended 31 December 2022
Year ended 30 June 2023
£m
£m
£m
£m
£m
£m
PROFIT FOR THE PERIOD
10.3
12.0
31.8
Items that may be reclassified subsequently to profit or loss
Foreign exchange translation differences
(2.1)
(4.5)
(27.2)
Fair value movement on net investment hedges
(0.4)
(0.9)
-
Fair value movement on cash flow hedges
(1.3)
0.6
0.8
Tax relating to components of other comprehensive expense
0.3
0.7
3.1
(3.5)
(4.1)
(23.3)
Items that may not be reclassified subsequently to profit or loss
Actuarial losses on retirement benefit obligations
(9.0)
(36.4)
(40.4)
Movement on pension asset recognition restriction
9.1
36.9
38.3
Release of additional pension liability
–
–
3.0
Gain on equity instruments measured at fair value
0.2
1.1
1.7
Tax relating to components of other comprehensive expense/(income)
-
(0.3)
(1.2)
0.3
1.3
1.4
OTHER COMPREHENSIVE EXPENSE FOR THE PERIOD
(3.2)
(2.8)
(21.9)
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD
7.1
9.2
9.9
ATTRIBUTABLE TO:
Owners of the Company
10.3
10.9
11.1
Non-controlling interest
(3.2)
(1.7)
(1.2)
7.1
9.2
9.9
GENUS PLC
CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
For the six months ended 31 December 2023
Called up share capital £m
Share premium account £m
Own shares £m
Translation reserve £m
Hedging reserve £m
Retained earnings £m
Total £m
Non- controlling interest £m
Total equity £m
BALANCE AT 30 JUNE 2022
6.6
179.1
(0.1)
50.9
1.4
340.6
578.5
(6.4)
572.1
Foreign exchange translation differences, net of tax
–
–
–
(24.2)
–
–
(24.2)
0.3
(23.9)
Fair value movement on net investment hedges, net of tax
–
–
–
-
–
–
-
–
-
Fair value movement on cash flow hedges, net of tax
–
–
–
–
0.6
–
0.6
–
0.6
Gain on equity instruments measured at fair value, net of tax
–
–
–
–
–
0.7
0.7
–
0.7
Actuarial loss on retirement benefit obligations, net of tax
–
–
–
–
–
(30.3)
(30.3)
–
(30.3)
Movement on pension asset recognition restriction, net of tax
–
–
–
–
–
28.7
28.7
–
28.7
Recognition of additional pension liability, net of tax
–
–
–
–
–
2.3
2.3
–
2.3
Other comprehensive (expense)/income for the year
–
–
–
(24.2)
0.6
1.4
(22.2)
0.3
(21.9)
Profit/(loss) for the year
–
–
–
–
–
33.3
33.3
(1.5)
31.8
Total comprehensive income/(expense) for the year
–
–
–
(24.2)
0.6
34.7
11.1
(1.2)
9.9
Recognition of share-based payments, net of tax
–
–
–
–
–
6.3
6.3
–
6.3
Dividends
–
–
–
–
–
(21.0)
(21.0)
–
(21.0)
Adjustment arising from change in non-controlling interest and written put option
–
–
–
–
–
–
–
(0.1)
(0.1)
BALANCE AT 30 JUNE 2023
6.6
179.1
(0.1)
26.7
2.0
360.6
574.9
(7.7)
567.2
Foreign exchange translation differences, net of tax
–
–
–
(2.3)
–
–
(2.3)
0.1
(2.2)
Fair value movement on net investment hedges, net of tax
–
–
–
(0.3)
–
–
(0.3)
–
(0.3)
Fair value movement on cash flow hedges, net of tax
–
–
–
–
(1.0)
–
(1.0)
–
(1.0)
Gain on equity instruments measured at fair value, net of tax
–
–
–
–
–
0.2
0.2
–
0.2
Actuarial losses on retirement benefit obligations, net of tax
–
–
–
–
–
(6.8)
(6.8)
–
(6.8)
Movement on pension asset recognition restriction, net of tax
–
–
–
–
–
6.9
6.9
–
6.9
Other comprehensive expense for the period
–
–
–
(2.6)
(1.0)
0.3
(3.3)
0.1
(3.2)
Profit/(loss) for the period
–
–
–
–
–
13.5
13.5
(3.2)
10.3
Total comprehensive income for the period
–
–
–
(2.6)
(1.0)
13.8
10.2
(3.1)
7.1
Recognition of share-based payments, net of tax
–
–
–
–
–
3.9
3.9
–
3.9
Dividends
–
–
–
–
–
(14.2)
(14.2)
–
(14.2)
Adjustment arising from change in non-controlling interest and written put option
–
–
–
–
–
–
–
8.9
8.9
BALANCE AT 31 DECEMBER 2023
6.6
179.1
(0.1)
24.1
1.0
364.1
574.8
(1.9)
572.9
Called up share capital £m
Share premium account £m
Own shares £m
Translation reserve £m
Hedging reserve £m
Retained earnings £m
Total £m
Non- controlling interest £m
Total equity £m
BALANCE AT 30 JUNE 2022
6.6
179.1
(0.1)
50.9
1.4
340.6
578.5
(6.4)
572.1
Foreign exchange translation differences, net of tax
–
–
–
(3.7)
–
–
(3.7)
(0.3)
(4.0)
Fair value movement on net investment hedges, net of tax
–
–
–
(0.7)
–
–
(0.7)
–
(0.7)
Fair value movement on cash flow hedges, net of tax
–
–
–
–
0.6
–
0.6
–
0.6
Gain on equity instruments measured at fair value, net of tax
–
–
–
–
–
0.8
0.8
–
0.8
Actuarial losses on retirement benefit obligations, net of tax
–
–
–
–
–
(29.4)
(29.4)
–
(29.4)
Movement on pension asset recognition restriction, net of tax
–
–
–
–
–
29.9
29.9
–
29.9
Other comprehensive expense for the period
–
–
–
(4.4)
0.6
1.3
(2.5)
(0.3)
(2.8)
Profit/(loss) for the period
–
–
–
–
–
13.4
13.4
(1.4)
12.0
Total comprehensive income for the period
–
–
–
(4.4)
0.6
14.7
10.9
(1.7)
9.2
Recognition of share-based payments, net of tax
–
–
–
–
–
2.9
2.9
–
2.9
Dividends
–
–
–
–
–
(14.2)
(14.2)
–
(14.2)
Adjustment arising from change in non-controlling interest and written put option
–
–
–
–
–
–
–
(0.1)
(0.1)
BALANCE AT 31 DECEMBER 2022
6.6
179.1
(0.1)
46.5
2.0
344.0
578.1
(8.2)
569.9
GENUS PLC
CONDENSED CONSOLIDATED BALANCE SHEET
As at 31 December 2023
31 December 2023 £m
31 December 2022 £m
30 June 2023 £m
ASSETS
Goodwill
111.9
111.7
107.8
Other intangible assets
67.5
68.4
66.2
Biological assets
319.3
322.7
318.2
Property, plant and equipment
190.2
168.3
164.4
Interests in joint ventures and associates
53.1
49.1
53.5
Other investments
4.2
11.7
8.8
Derivative financial assets
1.1
2.6
4.9
Other receivables
10.2
8.1
8.2
Deferred tax assets
19.0
10.1
16.5
TOTAL NON-CURRENT ASSETS
776.5
752.7
748.5
Inventories
65.6
59.2
61.3
Biological assets
31.0
30.9
23.8
Trade and other receivables
134.4
135.9
132.1
Cash and cash equivalents
42.0
42.3
36.3
Income tax receivable
3.2
2.0
4.0
Derivative financial assets
1.2
0.9
1.5
Asset held for sale
-
0.2
-
TOTAL CURRENT ASSETS
277.4
271.4
259.0
TOTAL ASSETS
1,053.9
1,024.1
1,007.5
LIABILITIES
Trade and other payables
(105.3)
(110.8)
(122.0)
Interest-bearing loans and borrowings
(7.0)
(7.3)
(4.2)
Provisions
(1.9)
(2.1)
(1.8)
Deferred consideration
(0.6)
–
–
Obligations under leases
(11.5)
(9.9)
(10.0)
Tax liabilities
(1.0)
(1.8)
(7.4)
Derivative financial liabilities
(1.6)
(1.7)
(1.8)
TOTAL CURRENT LIABILITIES
(128.9)
(133.6)
(147.2)
Interest-bearing loans and borrowings
(226.2)
(214.9)
(196.0)
Retirement benefit obligations
(6.6)
(7.3)
(6.9)
Provisions
(10.3)
(11.0)
(10.3)
Deferred consideration
(0.6)
(0.6)
(0.6)
Deferred tax liabilities
(54.2)
(55.8)
(51.2)
Derivative financial liabilities
(6.8)
(6.3)
(6.2)
Obligations under leases
(47.4)
(24.7)
(21.9)
TOTAL NON-CURRENT LIABILITIES
(352.1)
(320.6)
(293.1)
TOTAL LIABILITIES
(481.0)
(454.2)
(440.3)
NET ASSETS
572.9
569.9
567.2
EQUITY
Called up share capital
6.6
6.6
6.6
Share premium account
179.1
179.1
179.1
Own shares
(0.1)
(0.1)
(0.1)
Translation reserve
24.1
46.5
26.7
Hedging reserve
1.0
2.0
2.0
Retained earnings
364.1
344.0
360.6
EQUITY ATTRIBUTABLE TO OWNERS OF THE COMPANY
574.8
578.1
574.9
Non-controlling interest
3.6
(2.5)
(2.2)
Put option over non-controlling interest
(5.5)
(5.7)
(5.5)
TOTAL NON-CONTROLLING INTEREST
(1.9)
(8.2)
(7.7)
TOTAL EQUITY
572.9
569.9
567.2
GENUS PLC
CONDENSED CONSOLIDATED GROUP STATEMENT OF CASH FLOWS
For the six months ended 31 December 2023
Six months ended 31 December 2023 £m
Six months ended 31 December 2022 £m
Year ended 30 June
2023 £m
NET CASH FLOW FROM OPERATING ACTIVITIES
6.0
11.8
50.4
CASH FLOWS FROM INVESTING ACTIVITIES
Dividends received from joint ventures and associates
4.5
–
2.6
Joint venture and associate loan investment
-
–
(1.9)
Acquisition of joint venture and associate
(1.2)
(2.0)
(1.0)
Acquisition of controlling interest in Xelect Limited (see note 19)
(2.9)
–
–
Sale of other investments
4.7
–
3.4
Acquisition of investments
-
(0.4)
(0.4)
Payment of deferred consideration
-
(0.8)
(0.8)
Purchase of property, plant and equipment
(9.0)
(10.7)
(25.9)
Purchase of intangible assets
(5.4)
(4.3)
(9.3)
Proceeds from sale of property, plant and equipment
0.6
–
2.4
NET CASH OUTFLOW FROM INVESTING ACTIVITIES
(8.7)
(18.2)
(30.9)
CASH FLOWS FROM FINANCING ACTIVITIES
Drawdown of borrowings
90.2
80.1
126.8
Repayment of borrowings
(57.8)
(47.2)
(111.7)
Payment of lease liabilities
(8.9)
(5.9)
(11.1)
Equity dividends paid
(14.2)
(14.2)
(21.0)
Dividend to non-controlling interest
-
(0.1)
(0.1)
Debt issue costs
-
(1.1)
(1.1)
NET CASH INFLOW/(OUTFLOW) FROM FINANCING ACTIVITIES
9.3
11.6
(18.2)
NET INCREASE IN CASH AND CASH EQUIVALENTS
6.6
5.2
1.3
Cash and cash equivalents at start of period
36.3
38.8
38.8
Net increase in cash and cash equivalents
6.6
5.2
1.3
Effect of exchange rate fluctuations on cash and cash equivalents
(0.9)
(1.7)
(3.8)
TOTAL CASH AND CASH EQUIVALENTS AT END OF PERIOD
42.0
42.3
36.3
GENUS PLC
ANALYSIS OF NET DEBT
For the six months ended 31 December 2023
At 1 July 2023
Net cash flows
Foreign exchange
Non-cash movement
At 31 December 2023
£m
£m
£m
£m
£m
Cash and cash equivalents
36.3
6.6
(0.9)
–
42.0
Interest-bearing loans - current
(4.2)
(2.3)
-
(0.5)
(7.0)
Lease liabilities - current
(10.0)
8.9
-
(10.4)
(11.5)
(14.2)
6.6
-
(10.9)
(18.5)
Interest-bearing loans - non-current
(196.0)
(30.1)
(0.1)
–
(226.2)
Lease liabilities - non-current
(21.9)
–
0.1
(25.6)
(47.4)
(217.9)
(30.1)
-
(25.6)
(273.6)
Total debt financing
(232.1)
(23.5)
-
(36.5)
(292.1)
Net debt
(195.8)
(16.9)
(0.9)
(36.5)
(250.1)
Included within non-cash movements is £36.0m in relation to net new leases and £0.5m in the unwinding of debt issue cost.
At 1 July 2022
Net cash flows
Foreign exchange
Non-cash movement
At 31 December 2022
£m
£m
£m
£m
£m
Cash and cash equivalents
38.8
5.2
(1.7)
–
42.3
Interest-bearing loans - current
(7.1)
0.4
(0.1)
(0.5)
(7.3)
Lease liabilities - current
(10.1)
5.9
0.1
(5.8)
(9.9)
(17.2)
6.3
-
(6.3)
(17.2)
Interest-bearing loans - non-current
(182.1)
(32.2)
(0.6)
–
(214.9)
Lease liabilities - non-current
(24.5)
–
0.3
(0.5)
(24.7)
(206.6)
(32.2)
(0.3)
(0.5)
(239.6)
Total debt financing
(223.8)
(25.9)
(0.3)
(6.8)
(256.8)
Net debt
(185.0)
(20.7)
(2.0)
(6.8)
(214.5)
Net debt is gross debt, made up of unsecured bank loans and overdrafts and obligations under finance leases, with a deduction for cash and cash equivalents.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240221222132/en/
Enquiries:
Genus plc (Jorgen Kokke, Chief Executive Officer / Alison Henriksen, Chief Financial Officer) Tel: +44 1256 345970
Buchanan (Charles Ryland / Sophie Wills / Verity Parker) Tel: +44 207 4665000
1 Year Genius Chart |
1 Month Genius Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions